hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06367231, orgStudyIdInfo id: Pro00134554, briefTitle: SCGs as a Proxy for Determining the Cognitive Status of Older Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-07-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: University of Alberta, class: OTHER, descriptionModule briefSummary: Detecting memory problems early is crucial for treating conditions like Mild Cognitive Impairment (MCI), which often leads to dementia. Currently, doctors use tests in clinics to check for these issues. However, there's a growing need for better methods to monitor our cognitive skills over time. Computer games emerge as a cost-effective solution for assessing the brain functions of older adults.In our study, we are investigating the potential of computer games to reflect the cognitive skills of older adults. We developed the VibrantMinds platform, featuring five games: Whack-a-Mole, Bejeweled, Mahjong Solitaire, Word Search, and Memory Game. We have evaluated these games for ease of use, enjoyment, and their impact on brain functions. Now, our goal is to determine whether these games can offer valuable insights into the cognitive skills of older adults.We are collecting demographic data, game-playing data, and cognitive test results. Our analysis will determine the correlation between game data, cognitive test outcomes, and demographic information. Additionally, we will assess both the perceived and observed engagement of older adults as they play the games., conditionsModule conditions: Mild Cognitive Impairment, conditions: Dementia, conditions: Alzheimer Disease, conditions: Healthy Aging, conditions: Cognitive Decline, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 58, type: ESTIMATED, armsInterventionsModule interventions name: VibrantMinds, outcomesModule primaryOutcomes measure: Cognition - Global, secondaryOutcomes measure: Cognition - Global, secondaryOutcomes measure: Cognition - Executive Function, secondaryOutcomes measure: Game Performance, secondaryOutcomes measure: Game Engagement, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06367192, orgStudyIdInfo id: SKITS2, secondaryIdInfos id: K23HL166697, type: NIH, link: https://reporter.nih.gov/quickSearch/K23HL166697, briefTitle: School Readiness Intervention for Preschool Children With Sickle Cell Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-10, completionDateStruct date: 2028-10, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: St. Jude Children's Research Hospital, class: OTHER, collaborators name: National Heart, Lung, and Blood Institute (NHLBI), descriptionModule briefSummary: The study participant is being asked to take part in this clinical trial, a type of research study, because the participant is a young child with sickle cell disease or the caregiver of a child with sickle cell disease. This study is being done to test a school readiness program for children with sickle cell disease (ages 4-6 years old).Primary ObjectiveAssess feasibility and acceptability of an adapted school readiness intervention among preschool children (ages 4-6) diagnosed with sickle cell disease.Secondary ObjectivesObjective 1:Measure preliminary efficacy of the adapted school readiness intervention compared to routine care among preschool children ages (4-6) diagnosed with sickle cell disease.Objective 2:Examine implementation factors (i.e., barriers and facilitators) during post-intervention., conditionsModule conditions: Sickle Cell Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: The adapted Kids in Transition to School Intervention, interventions name: Standard school resources, outcomesModule primaryOutcomes measure: Feasibility of Intervention Measure, primaryOutcomes measure: Acceptability of Intervention Measure, secondaryOutcomes measure: Bracken School Readiness Assessment - 3rd Edition, secondaryOutcomes measure: Woodcock Johnson Tests of Achievement - Fourth Edition, secondaryOutcomes measure: NIH Toolbox Flanker Test, secondaryOutcomes measure: Head-Toes-Knees-Shoulders Revised, secondaryOutcomes measure: Behavior Rating Inventory of Executive Functioning Preschool or Child, secondaryOutcomes measure: The Parenting Scale, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 6 Years, stdAges: CHILD, contactsLocationsModule locations facility: St. Jude Children's Research Hospital, city: Memphis, state: Tennessee, zip: 38105, country: United States, contacts name: ANDREW HEITZER, PhD, role: CONTACT, contacts name: ANDREW HEITZER, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.14953, lon: -90.04898, hasResults: False
protocolSection identificationModule nctId: NCT06367179, orgStudyIdInfo id: 202401039RINC, briefTitle: Virtual Reality and AI Wound-detecting System, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-22, primaryCompletionDateStruct date: 2025-02-04, completionDateStruct date: 2025-02-04, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: National Taiwan University Hospital, class: OTHER, descriptionModule briefSummary: This study is an experimental study. The main caregivers of pressure injury patients in the plastics surgery ward and general medicine ward of the hospital in Taipei City who are over 20 years old, have good communication skills in Chinese and Taiwanese or who can read Chinese are the research objects. During the study process, pre-tests will be given to the accepted subjects, which are the correctness evaluation scale of caregiver's pressure injury wound dressing change and caregiver self-efficacy scale, and then the accepted subjects will be divided into experimental group and control group. The experimental group will receive interventions of virtual reality and artificial intelligence wound detecting system, while the control group maintained the traditional pressure injury health education with oral introduction and health education leaflet. After the intervention measures are given, a post-test (same as the pre-test content) will be conducted within two days. Finally, analyze the effectiveness of the intervention of virtual reality pressure injury education video and artificial intelligence wound detecting system on caregivers of pressure injury improve wound care correctness and increase self-efficacy., conditionsModule conditions: Pressure Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 92, type: ESTIMATED, armsInterventionsModule interventions name: Virtual reality and AI use, interventions name: Health education leaflet, outcomesModule primaryOutcomes measure: Accurate dressing change rate of pressure injury, secondaryOutcomes measure: Pressure injury dressing change of self-efficacy, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Taiwan University Hospital, status: RECRUITING, city: Taipei, zip: 100225, country: Taiwan, contacts name: Cian Huei Wang, role: CONTACT, phone: (02)23123456, phoneExt: 263502, email: chw0710@ntuh.gov.tw, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06367166, orgStudyIdInfo id: RyazanSMU, briefTitle: Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Ryazan State Medical University, class: OTHER, descriptionModule briefSummary: The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin)., conditionsModule conditions: Varicose Veins of Lower Limb, conditions: Varix, conditions: Vascular Diseases, conditions: Leg Edema, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients with varicose veins will be assigned to different treatments to assess the venous wall remodeling parameters throughout treatment, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule interventions name: "Venarus®" (diosmin and hesperidin), interventions name: Endovenous laser ablation (EVLA) with miniphlebectomy, interventions name: Elastic compression, interventions name: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores, outcomesModule primaryOutcomes measure: changes in biomarkers of venous wall remodeling, primaryOutcomes measure: Changes in biomarkers expression in venous wall, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: RyazanSMU, city: Ryazan, country: Russian Federation, geoPoint lat: 54.6269, lon: 39.6916, hasResults: False
protocolSection identificationModule nctId: NCT06367153, orgStudyIdInfo id: 1447-0007, secondaryIdInfos id: 2023-510461-10-00, type: REGISTRY, domain: CTIS, secondaryIdInfos id: U1111-1303-9187, type: REGISTRY, domain: WHO International Clinical Trials Registry Platform (ICTRP), briefTitle: A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-07, primaryCompletionDateStruct date: 2024-08-24, completionDateStruct date: 2024-08-24, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Boehringer Ingelheim, class: INDUSTRY, descriptionModule briefSummary: The main objective of this trial is to investigate the effect of multiple oral doses of BI 1569912 on the pharmacokinetics of a single oral dose of repaglinide, midazolam and bupropion (i.e. sensitive CYP2C8, CYP3A4 and CYP2B6 substrates)., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: CROSSOVER, interventionModelDescription: Patients cross over from test treatment (T) to reference treatment (R) (two periods, fixed sequence)., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: BI 1569912, interventions name: repaglinide, interventions name: midazolam, interventions name: bupropion, outcomesModule primaryOutcomes measure: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞), secondaryOutcomes measure: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz), secondaryOutcomes measure: Maximum measured concentration of the analyte in plasma (Cmax), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06367140, orgStudyIdInfo id: SYU 2021-06-001-002, briefTitle: Effects of Electromyography-Triggered Constraint-Induced Movement Cycling Therapy on Patients With Chronic Stroke, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-01-01, primaryCompletionDateStruct date: 2022-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Sahmyook University, class: OTHER, collaborators name: Seoul National University Hospital, collaborators name: Kyungdong University, descriptionModule briefSummary: The study investigates the potential of Electromyography (EMG)-triggered Constraint-Induced Movement Cycling Therapy (CIMCT) versus General Cycling Training (GCT) to enhance balance, strength, and daily activities in chronic stroke patients. Over a period of four weeks, this single-blind randomized controlled trial aims to explore how these interventions can assist in stroke rehabilitation. The research has been approved by the Ethics Committee of Kyungdong University and adheres to the ethical standards laid out in the Declaration of Helsinki., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: The evaluators were blinded to the intervention details of the participants., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 58, type: ACTUAL, armsInterventionsModule interventions name: EMG-triggered CIMCT device, interventions name: general cycling training, outcomesModule primaryOutcomes measure: Muscle Strength, primaryOutcomes measure: Static Balance, primaryOutcomes measure: Timed Up and Go (TUG), primaryOutcomes measure: Berg Balance Scale, primaryOutcomes measure: Functional Reach Test (FRT), primaryOutcomes measure: Modified Barthel Index (MBI), eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Physicla Therapy, Sahmyook University, city: Seoul, zip: 01795, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06367127, orgStudyIdInfo id: Pingfanghu, briefTitle: Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-10-09, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Shanghai Changzheng Hospital, class: OTHER, descriptionModule briefSummary: Hepatic encephalopathy is a brain dysfunction caused by liver insufficiency and/or porto-systemic shunt. It manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. According to the symptoms, it is classified as covert HE (CHE) and overt HE (OHE). CHE can progress to OHE and is associated with reduced driving ability, increased risk of accidents and hospitalization and weakened health-related quality of life, resulting in poor prognosis and socio-economic status. However, due to the absence of readily identifiable clinical symptoms and signs, CHE is often neglected in clinical practice.Presently, the diagnosis of CHE depends on psychometric and neurophysiological tests, including the psychometric hepatic encephalopathy score (PHES), critical flicker frequency (CFF) test, continuous reaction time (CRT) test, inhibitory control test, the SCAN test, and electroencephalography. Among them, PHES is most widely used and recommended by several guidelines. However, it is difficult to screen CHE among all cirrhotic patients in the clinic using PHES because of the time required and a dependence on trained experts.Moving beans from one container to another with tweezers involves dexterity, agility and coordination.The hypothesis was that the utility of the Clamping Bean Test (CBT) will enable early screening patients with CHE., conditionsModule conditions: Hepatic Encephalopathy, conditions: Covert Hepatic Encephalopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: Number of Beans Clamping in 1 minute, secondaryOutcomes measure: Participants' feedback on CBT1 test, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Changzheng hospital, city: Shanghai, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06367114, orgStudyIdInfo id: ssCART-19-II-1, briefTitle: Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, class: INDUSTRY, collaborators name: The First Affiliated Hospital of Soochow University, collaborators name: Peking University People's Hospital, descriptionModule briefSummary: This study is a Phase II, single-arm, open-label, non-randomized, dose-escalation clinical trial to evaluate the efficacy and safety of ssCART-19 Cell Injection in the treatment of patients with CD19 positive Relapsed or Refractory acute lymphoblastic leukemia, including central nervous system infiltration., conditionsModule conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: ssCART-19, interventions name: Fludarabine, interventions name: Cyclophosphamide, outcomesModule primaryOutcomes measure: Determine the efficacy of ssCART-19 cells in patients with CD19-positive relapsed or refractory acute B lymphoblastic leukemia (r/r B-ALL)., secondaryOutcomes measure: Observe the anti-tumor response of ssCART-19 cells to refractory or relapsed acute lymphoblastic leukemia., secondaryOutcomes measure: Best overall response (BOR)assessment during the 3 months after ssCART-19 infusion., secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Recurrence free survival (RFS), secondaryOutcomes measure: Event Free Survival (EFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Incidence of adverse events following ssCART-19 infusion, secondaryOutcomes measure: Pharmacodynamic of ssCART-19 cells, secondaryOutcomes measure: Pharmacodynamic of ssCART-19 cells, secondaryOutcomes measure: Pharmacodynamic of ssCART-19 cells, otherOutcomes measure: Anti-drug antibody, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., city: Shanghai, state: Shanghai, zip: 201210, country: China, geoPoint lat: 31.22222, lon: 121.45806, locations facility: The First Affiliated Hospital of Soochow University, city: Suzhou, country: China, contacts name: Depei Wu, Dr., role: CONTACT, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False
protocolSection identificationModule nctId: NCT06367101, orgStudyIdInfo id: 202002525B0, briefTitle: AR Stimulation Effects on Gait, Anxiety, and Brain Connectivity in Parkinson's Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-01-18, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2025-07-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Chang Gung University, class: OTHER, descriptionModule briefSummary: A project aims at addressing gait impairments and non-motor symptoms such as anxiety and stress in Parkinson's disease (PD) patients through a novel approach involving heart rate variability (HRV) feedback and Augmented Reality (AR) training. The project is based on the premise that improving HRV, which reflects the adaptability of the autonomic nervous system, can enhance both motor functions like gait and non-motor symptoms., conditionsModule conditions: Parkinson Disease(PD), designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: AR training with gait and HRV feedback, outcomesModule primaryOutcomes measure: Walking Speed, primaryOutcomes measure: Step Length, primaryOutcomes measure: Step Time, primaryOutcomes measure: Time-Domain Index of Heart Rate Variability (HRV)：Standard deviation of RR intervals (SDRR), primaryOutcomes measure: Time-Domain Index of HRV：pNN50, primaryOutcomes measure: Time-Domain Index of HRV：Root mean square of successive RR interval differences (RMSSD), primaryOutcomes measure: Frequency-Domain Index of HRV: Low Frequency (LF), primaryOutcomes measure: Frequency-Domain Index of HRV: High Frequency (HF), primaryOutcomes measure: Frequency-Domain Index of HRV: Ratio of LF to HF Power, primaryOutcomes measure: Total Time to Complete the Time Up and Go test (TUG test), secondaryOutcomes measure: Double Support Time, secondaryOutcomes measure: Single Support Time, secondaryOutcomes measure: Swing Time, secondaryOutcomes measure: Stance Time, secondaryOutcomes measure: Cadence, secondaryOutcomes measure: Total UPDRS-III Score, secondaryOutcomes measure: Total NFOG-Q Score, secondaryOutcomes measure: Overall PDQ-39 Score, secondaryOutcomes measure: Total HADS Score, secondaryOutcomes measure: Overall PSQI Score, secondaryOutcomes measure: Non-linear Index of HRV: SD1, secondaryOutcomes measure: Non-linear Index of HRV: SD2, secondaryOutcomes measure: Non-linear Index of HRV: Ratio of SD1-to-SD2, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chang Gung University, status: RECRUITING, city: Taoyuan, zip: 333, country: Taiwan, contacts name: Ya-Ju Chang, PhD, role: CONTACT, phone: 88632118800, phoneExt: 5515, email: yjchang@mail.cgu.edu.tw, geoPoint lat: 24.95233, lon: 121.20193, hasResults: False